AVITA Medical Inc (ASX: AVH) Share Price and News
Price
Movement
52 Week Range
1 Year Return
() Chart and Price Data
Fundamental Company Figures
Data provided by Morningstar.Avita Therapeutics Inc (ASX: AVH) Latest News
Why the Avita Medical (ASX:AVH) share price is slipping lower today
Daniel Ewing | February 17, 2021 3:32pm
How do Avita Medical (ASX:AVH) shares stack up against Polynovo and Aroa Biosurgery?
Rhys Brock | February 17, 2021 9:47am
Why AVITA, Baby Bunting, Kathmandu, & Webjet shares are sinking
James Mickleboro | February 12, 2021 1:07pm
Recent Stock Announcements
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About AVITA Medical Inc (ASX: AVH)
Avita Therapeutics Inc (ASX: AVH) is a medical technology company that specialises in regenerative medicine. Avita’s leading product, the RECELL System, was developed to address unmet medical needs in burns. The RECELL System is used to prepare ‘spray-on skin cells’ by using a small amount of the patient’s own skin. This is a revolutionary way to treat severe burns and significantly reduces the amount of donor skin required.
RECELL was granted US Food and Drug Administration (FDA) approval in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Since then, Avita has been undertaking studies to assess the use of the RECELL System in other applications. This includes the treatment of pediatric scald injuries, soft tissue reconstruction and vitiligo.
The Avita share price exploded in 2019, going from $0.081 to finish the year a phenomenal 696% higher at $0.645. With this, Avita earned itself a spot in the S&P/ASX 200 Index (ASX: XJO), as well as a place on many investors’ ASX watchlists.
Share Price History
Data provided by Morningstar.| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Apr 2021 | $5.36 | $-0.03 | -0.56% | 361,259 | $5.40 | $5.45 | $5.33 |
| 15 Apr 2021 | $5.39 | $0.08 | 1.51% | 205,156 | $5.33 | $5.42 | $5.31 |
| 14 Apr 2021 | $5.31 | $0.01 | 0.19% | 1,710,250 | $5.34 | $5.42 | $5.26 |
| 13 Apr 2021 | $5.30 | $-0.16 | -2.93% | 193,037 | $5.41 | $5.43 | $5.30 |
| 12 Apr 2021 | $5.46 | $-0.07 | -1.27% | 167,526 | $5.53 | $5.53 | $5.40 |
| 09 Apr 2021 | $5.53 | $0.13 | 2.41% | 305,795 | $5.45 | $5.54 | $5.43 |
| 08 Apr 2021 | $5.40 | $0.08 | 1.50% | 247,751 | $5.35 | $5.47 | $5.32 |
| 07 Apr 2021 | $5.32 | $-0.08 | -1.48% | 188,458 | $5.40 | $5.41 | $5.30 |
| 06 Apr 2021 | $5.40 | $0.07 | 1.31% | 308,936 | $5.42 | $5.51 | $5.38 |
| 01 Apr 2021 | $5.33 | $0.26 | 5.13% | 417,830 | $5.15 | $5.34 | $5.11 |
| 31 Mar 2021 | $5.07 | $-0.06 | -1.17% | 228,982 | $5.13 | $5.19 | $5.06 |
| 30 Mar 2021 | $5.13 | $-0.11 | -2.10% | 509,960 | $5.21 | $5.21 | $5.05 |
| 29 Mar 2021 | $5.24 | $-0.12 | -2.24% | 269,055 | $5.40 | $5.43 | $5.24 |
| 26 Mar 2021 | $5.36 | $0.01 | 0.19% | 318,943 | $5.49 | $5.49 | $5.33 |
| 25 Mar 2021 | $5.35 | $-0.15 | -2.73% | 379,278 | $5.46 | $5.46 | $5.32 |
| 24 Mar 2021 | $5.50 | $-0.19 | -3.34% | 377,693 | $5.65 | $5.67 | $5.46 |
| 23 Mar 2021 | $5.69 | $0.18 | 3.27% | 451,609 | $5.65 | $5.91 | $5.65 |
| 22 Mar 2021 | $5.51 | $0.16 | 2.99% | 397,955 | $5.37 | $5.61 | $5.35 |
| 19 Mar 2021 | $5.35 | $-0.20 | -3.60% | 3,800,701 | $5.54 | $5.58 | $5.35 |
| 18 Mar 2021 | $5.55 | $-0.09 | -1.60% | 304,361 | $5.64 | $5.70 | $5.52 |
| 17 Mar 2021 | $5.64 | $-0.10 | -1.74% | 430,386 | $5.74 | $5.79 | $5.57 |
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| Cede & Co | 40,188,890 | 37.44% |
| HSBC Custody Nominees (Australia) Limited (I) | 7,253,182 | 6.76% |
| Citicorp Nominees Pty Limited | 7,045,639 | 6.56% |
| J P Morgan Nominees Australia Pty Limited | 6,687,839 | 6.23% |
| National Nominees Limited | 5,395,728 | 5.03% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,816,130 | 1.69% |
| Mr Michael Perry | 1,263,045 | 1.18% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 1,252,369 | 1.17% |
| Cs Fourth Nominees Pty Limited | 1,097,835 | 1.02% |
| HSBC Custody Nominees (Australia) Limited (II) | 735,579 | 0.69% |
| Ateq Investments Pty Ltd | 590,000 | 0.55% |
| BNP Paribas Nominees Pty Ltd | 490,104 | 0.46% |
| BNP Paribas Nominees Pty Ltd (I) | 412,302 | 0.38% |
| Warbont Nominees Pty Ltd | 403,116 | 0.38% |
| Brispot Nominees Pty Ltd | 359,195 | 0.33% |
| Mr Adrian Simun Puljich | 271,765 | 0.25% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd | 244,938 | 0.23% |
| Dibbens Developments Pty Limited | 225,000 | 0.21% |
| Mr Anthony Mark Saia & Mrs Carmen Saia | 217,500 | 0.20% |
| Citicorp Nominees Pty Limited (I) | 213,979 | 0.20% |
FAQ
Will Avita Medical pay a dividend in 2020?
Avita Therapeutics shares do not currently include a dividend payment. The company has made no announcements regarding paying a dividend in 2020.
Does Avita Medical offer a DRP?
No, Avita Therapeutics does not currently offer a dividend reinvestment plan (DRP).